High-density lipoprotein (HDL) cholesterol and
triglyceride levels in people as young as age 35 were linked with
Alzheimer's dementia decades later in life, longitudinal data from the
Framingham Heart Study showed.
Risk of Alzheimer's dementia fell by 15.4% during early adulthood
(ages 35 to 50) and by 17.8% during middle adulthood (ages 51 to 60) for
every 15 mg/dL increase in HDL cholesterol, reported Xiaoling Zhang,
MD, PhD, of Boston University School of Medicine, and co-authors in Alzheimer's & Dementia.
A
15 mg/dL increase in blood glucose measured during middle adulthood was
associated with a 14.5% increased Alzheimer's risk, they added.
Triglyceride levels were associated with Alzheimer's only in the early
adulthood group. Findings remained significant after adjusting for
treatment.
"These findings show for the first time that cardiovascular risk
factors, including HDL, which has not been consistently reported as a
strong risk factor for Alzheimer's disease, contribute to future risk of
Alzheimer's disease starting as early as age 35," Zhang said in a
statement.
"While our findings confirm other studies that linked cholesterol and
glucose levels measured in blood with future risk of Alzheimer's
disease, we have shown for the first time that these associations extend
much earlier in life than previously thought," added co-author Lindsay
Farrer, PhD, also of Boston University.
The researchers looked at the influence of vascular risk factors on incident Alzheimer's dementia over time among Framingham Heart Study Offspring
participants, a group that's been evaluated since 1971. Data on lipid
fractions, glucose, blood pressure, BMI, and smoking were obtained
prospectively from participants across nine quadrennial examinations.
Age-,
sex-, and education-adjusted models were tested for each risk factor
measured at each exam and within three adult age groups: early adults
(ages 35 to 50, median 41), middle adults (ages 51 to 60, median 54),
and late adults (ages 61 to 70, median 63.5).
A total of 271 participants (167 women, 104 men) diagnosed with
Alzheimer's dementia were included in the analysis as cases. Of these,
225 people were without stroke, 24 people had Alzheimer's and stroke,
and 24 people had mixed Alzheimer's and vascular dementia. People with a
diagnosis of non-Alzheimer's dementia were excluded. Controls included
4,867 cognitively normal participants.
Mean follow-up periods for people in the early, middle, and late age
groups were 35.2 years, 25.8 years, and 18.5 years, respectively. As
participants grew older, they tended to have higher triglyceride and
glucose levels, higher systolic and diastolic blood pressure, and lower
HDL cholesterol levels. They also were more likely to be treated for
diabetes, hypertension, and dyslipidemia.
Incident Alzheimer's dementia was negatively associated with HDL
cholesterol for every 15 mg/dL increase in early adulthood (HR 0.85, 95%
CI 0.72-0.99, P=0.041) and in middle adulthood (HR 0.82, 95% CI 0.70-0.96, P=0.014).
This association remained significant with a similar effect size in the
middle adulthood group when adjusted for dyslipidemia treatment (P=0.022).
Analyses also showed:
- Triglyceride
levels were associated with Alzheimer's dementia only in the early
adulthood group, before (HR 1.33, 95% CI 1.02-1.57, P=0.0013) and after (HR 1.30, 95% CI 1.10-1.54, P=0.0018) adjusting for dyslipidemia treatment
- Blood
glucose in middle adulthood was associated with Alzheimer's dementia
per 15 mg/dL increase, before (HR 1.15, 95% CI 1.06-1.23, P=0.00029) and after (HR 1.18, 95% CI 1.08-1.29, P=0.00036) adjusting for diabetes treatment
- Diastolic
blood pressure in late adulthood was associated with Alzheimer's
dementia per 10 mm increase, before (HR 1.14, 95% CI 1.01-1.29, P=0.041) and after (HR 1.14, 95% CI 1.00-1.29, P=0.044) adjusting for treatment
- Other
vascular risk factors, including low-density lipoprotein (LDL)
cholesterol, total cholesterol, BMI, smoking, and systolic blood
pressure, were not associated with Alzheimer's dementia in any stage of
adulthood (P>0.05)
Future development of
Alzheimer's dementia was progressively higher and likely to occur
earlier among people who had blood glucose in pre-diabetic (100 to 126
mg/dL) and diabetic (>126 mg/dL) ranges in early adulthood and middle
adulthood.
"Intervention
targeting cholesterol and glucose management starting in early
adulthood can help maximize cognitive health in later life," Farrer
suggested.
That idea is supported by previous studies of Framingham Offspring
participants showing that elevated coronary heart disease risk and
metabolic syndrome were associated with lower cognitive performance at age 55, Zhang and co-authors noted.
"However, our results do not distinguish whether the influences of
these risk factors on the development of Alzheimer's disease may be
particularly damaging during early adulthood and midlife or reflect
longer accumulated risk exposure," they wrote.
The study had several limitations, the researchers acknowledged. All
participants were white, and some early measurements of lipids and
glucose were not under fasting conditions. In addition, the findings
were based on analyses of one-time measurements.
-
Judy George
covers neurology and neuroscience news for MedPage Today, writing about
brain aging, Alzheimer’s, dementia, MS, rare diseases, epilepsy,
autism, headache, stroke, Parkinson’s, ALS, concussion, CTE, sleep,
pain, and more. Follow
Disclosures
This work was
supported by the Framingham Heart Study's National Heart, Lung, and
Blood Institute contract, Boston University School of Medicine, the NIH,
and the Alzheimer's Association.
Zhang had no disclosures.
Co-authors
reported relationships with the Alzheimer's Drug Discovery Foundation,
American Heart Association, Gates Ventures, Mass Mutual Insurance,
Signant Health, Biogen, GlaxoSmithKline, Novo Nordisk, High Lantern, and
the NIH.